Paper42652154
Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.
Gajjar A and 8 others. Biomedicines, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions. Papers, record 42652154. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42652154
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References104
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9535173 | New developments in antitumor anthracyclines. | Pharmacol Ther | 1997 | https://conductscience.org/library/papers/9535173 | PubMed |
| 2 | 9193323 | Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9193323 | PubMed |
| 3 | 21689398 | Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. | Breast Cancer Res | 2011 | https://conductscience.org/library/papers/21689398 | PubMed |
| 4 | 37479951 | Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies. | Cardiovasc Toxicol | 2023 | https://conductscience.org/library/papers/37479951 | PubMed |
| 5 | 38582914 | A comprehensive pediatric cardio-oncology program: a single institution approach to cardiovascular care for pediatric patients with cancer and childhood cancer survivors. | Cardiooncology | 2024 | https://conductscience.org/library/papers/38582914 | PubMed |
| 6 | 33847848 | The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. | Cardiovasc Drugs Ther | 2022 | https://conductscience.org/library/papers/33847848 | PubMed |
| 7 | 29567210 | Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. | J Am Coll Cardiol | 2018 | https://conductscience.org/library/papers/29567210 | PubMed |
| 8 | 39801647 | Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. | JACC CardioOncol | 2024 | https://conductscience.org/library/papers/39801647 | PubMed |
| 9 | 33006257 | Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. | Eur J Heart Fail | 2020 | https://conductscience.org/library/papers/33006257 | PubMed |
| 10 | 25948538 | Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. | Circulation | 2015 | https://conductscience.org/library/papers/25948538 | PubMed |
| 11 | 34088867 | Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. | Pharmacol Rev | 2021 | https://conductscience.org/library/papers/34088867 | PubMed |
| 12 | 31761945 | A population-based study of cardiovascular disease mortality risk in US cancer patients. | Eur Heart J | 2019 | https://conductscience.org/library/papers/31761945 | PubMed |
| 13 | 37301767 | Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer. | J Am Heart Assoc | 2023 | https://conductscience.org/library/papers/37301767 | PubMed |
| 14 | 26834065 | Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26834065 | PubMed |
| 15 | 26747086 | Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study. | Ann Intern Med | 2016 | https://conductscience.org/library/papers/26747086 | PubMed |
| 16 | 32231332 | Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. | Nat Rev Cardiol | 2020 | https://conductscience.org/library/papers/32231332 | PubMed |
| 17 | 32258060 | Cardiotoxicity of Anthracyclines. | Front Cardiovasc Med | 2020 | https://conductscience.org/library/papers/32258060 | PubMed |
| 18 | 35911522 | The role of cardiac computed tomography in predicting adverse coronary events. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35911522 | PubMed |
| 19 | 34557898 | Artificial intelligence in cardiovascular imaging-principles, expectations, and limitations. | Eur Heart J | 2021 | https://conductscience.org/library/papers/34557898 | PubMed |
| 20 | 31928066 | Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation. | Antioxid Redox Signal | 2020 | https://conductscience.org/library/papers/31928066 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42652154
GET https://conductscience.org/api/papers/v1/42652154/references?page=2